Đang chuẩn bị liên kết để tải về tài liệu:
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin’s lymphoma. Bortezomib is the first product to be approved for the treatment of patients with previously untreated MCL, for whom haematopoietic stem cell transplantation is unsuitable, and is used in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP). |

TÀI LIỆU LIÊN QUAN

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: A costeffectiveness analysis

Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: A costeffectiveness analysis based on trial data